B+
Bull case
25%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
ERNA
Ernexa TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive primary-source case is that management has linked pre-IND feedback, tech transfer, and a planned first-in-human path for ERNA-101, while the February 2026 financing reduced immediate cash pressure enough to pursue near-term preparatory work.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical and manufacturing execution risk is still substantial because ERNA-101 remains preclinical and must complete manufacturing, IND-enabling work, IND submission, and trial initiation before the thesis can move beyond a monitoring setup.
Momentum
93
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.14 · Bull $0.32 · Bear $0.05Analysis 2026-05-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-01 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $30.00
Why
Momentum93 · Δ7d -
Value41 · Δ7d 0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Clinical and manufacturing execution risk is still substantial because ERNA-101 remains preclinical and must complete manufacturing, IND-enabling work, IND submission, and trial initiation before the thesis can move beyond a monitoring setup.
- • Liquidity risk remains high: the 10-K disclosed about $1.9 million of year-end cash, operating cash burn, and substantial-doubt going-concern language despite the February 2026 financing.
- • The bearish read is that listing compliance and financing still dominate the story: Nasdaq deficiency risk remains active, another reverse split is queued, the company remains preclinical, and the 10-K still carries going-concern language even after the February raise.
Catalyst clock
2026-05-03
Reverse split execution and Nasdaq listing outcome
Lead driver: Value · See fundamentals
Momentum
93
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-17.2
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 93.4 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-01. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.14
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.05
Analysis reference price unavailable
Analysis 2026-05-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$6.63M
Beta
6.47
Shares Out
1.63M
P/E (TTM) · Derived
-0.1
P/S (TTM)
9497.16
P/FCF (TTM) · Derived
-0.29
Rev YoY
-100.0%
EPS YoY
-77.6%
Gross Margin
-26100.0%
Op Margin
-918700.0%
Net Debt
-$1.39M
Current Ratio
2.01
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data